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ABSTRACT 38 
Objective: To investigate whether cerebrospinal fluid (CSF) neurogranin concentrations are altered in 39 
sporadic Creutzfeldt-Jakob disease (CJD), comparatively with Alzheimer’s disease (AD), and 40 
associated with neuronal degeneration in brain tissue. 41 
Methods: CSF neurogranin, total-tau(tau), neurofilament light(NFL) and 14-3-3 protein were 42 
measured in neurological controls (NC,n=64), (AD (n=46) and CJD (n=81). The accuracy of 43 
neurogranin discriminating the three diagnostic groups was evaluated. Correlations between 44 
neurogranin and neurodegeneration biomarkers, demographic, genetic and clinical data were assessed. 45 
Additionally, neurogranin expression in post-mortem brain tissue was studied. 46 
Results: Compared to NC, CSF neurogranin concentrations were increased in CJD (4.75 times of NC; 47 
p<0.001, AUC (95%CI)=0.96 (0.93-0.99) and AD (1.94 times of NC; p<0.01, AUC (95%CI)=0.73 48 
(0.62-0.82), and were able to differentiate CJD from AD (p<0.001, AUC (95%CI)=0.85 (0.78-0.92)). 49 
CSF tau was increased in CJD (41 times of NC) and in AD (3.1 times of NC), both at p<0.001. In 50 
CJD, neurogranin positively correlated with tau (rho=0.55,p<0.001) and was higher in 14-3-3-51 
positivity (p<0.05), but showed no association with NFL (rho=0.08,p=0.46). CJD-MM1/MV1 cases 52 
displayed higher neurogranin levels than VV2 cases. Neurogranin was increased at early CJD disease 53 
stages and was a good prognostic marker of survival time in CJD. In brain tissue, neurogranin was 54 
detected in the cytoplasm, membrane and post-synaptic density fractions of neurons, with reduced 55 
levels in AD, and more significantly in CJD, where they correlated with synaptic and axonal markers. 56 
Conclusions: Neurogranin is a new biomarker of prion pathogenesis with diagnostic and prognostic 57 
abilities, which reflects the degree of neuronal damage in brain tissue in a CJD subtype manner. 58 
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 63 
INTRODUCTION   64 
Neurogranin is a calmodulin-binding protein abundantly expressed in the soma and dendrites of 65 
neurons of the telencephalon[1,2] involved in synaptic plasticity and long-term potentiation[3,4]. 66 
Neurogranin has been suggested to be a specific cerebrospinal fluid (CSF) Alzheimer’s disease (AD) 67 
biomarker, since its concentration is increased in AD, but not in other neurodegenerative diseases (i.e., 68 
frontotemporal dementia, Lewy body dementia, Parkinson’s disease, progressive supranuclear palsy, 69 
multiple system atrophy and Huntington’s disease)[5–7]. Although CSF neurogranin presents only 70 
moderate diagnostic value for AD[5,8], this can be improved when combined with other CSF 71 
biomarkers of AD such as tau and neurofilament light (NFL)[9]. In AD, CSF neurogranin displays 72 
strong positive correlation with other AD biomarkers such as tau and phospho-tau[5,10–13], while 73 
weak or no correlations were detected with amyloid-beta42, a biomarker of amyloid plaques 74 
load[5,10,13].  75 
A prognostic value for neurogranin in AD has been proposed, as its CSF concentration is 76 
differentially elevated in mild cognitive impairment (MCI) patients with biomarker AD-signature[11] 77 
as well as in MCI patients who progress to AD dementia compared to those who remain cognitively 78 
stable[10,13]. Similarly, CSF neurogranin correlates with rate of cognitive decline in MCI[14] and 79 
with reduction of brain volume in AD[8]. In cognitively normal individuals, CSF neurogranin is also 80 
useful in predicting future cognitive impairment[8]. Regrettably, neurogranin analysis in paired 81 
plasma-CSF samples indicated that the AD-specific increased CSF levels are not reproduced in 82 
plasma, discarding the potential use of blood neurogranin measurements for diagnostic or prognostic 83 
purposes[15].  84 
Although extensive work has been done in AD, data is lacking regarding neurogranin levels in other 85 
diseases presenting substantial synaptic and neuronal loss. This is the case of prion diseases, one of 86 
whose fundamental characteristics is synaptic degeneration and disorganization, which leads to 87 
neuronal loss and spongiform changes. Indeed, over a 30% reduction in the relative synaptic index has 88 
been reported in prion disease-affected brains compared to controls[16]. Similarly to AD, synaptic 89 
loss occurs at early stages of prion diseases[17], and it is suggested that synaptic pathology is initiated 90 
at the synaptic spine[18]. Experiments conducted in prion disease mouse models revealed that axon 91 
terminal degeneration and synaptic loss precede neuronal death and are associated with the onset of 92 
clinical symptomatology[19]. Sporadic Creutzfeldt-Jakob disease (CJD) is the most prevalent human 93 
prion disease characterized by rapidly progressive dementia and short disease duration [20]. The 94 
combination of genotype at codon 129 (methionine or valine) and PrPSc type (1 or 2 based on the size 95 
of protease resistant PrP fragments) gives rise to different CJD subtypes with characteristic disease 96 
phenotype and neuropathological features. Thus, synaptic and neuronal damage, neuroinflammation, 97 
deposition of pathogenic prion protein (PrPSc) and lesion profile occur in a well-defined regional- and 98 
subtype-specific manner[17,21–23].The most prevalent subtypes are CJDMM1/CJDMV1 (60-70% of 99 
the cases) with predominant cortical affection and, CJD VV2 (~16% of the cases), with prominent 100 
cerebellar affection [22]. Several pathological mechanisms are suggested to contribute to CJD 101 
synaptic pathology, including the accumulation of the abnormal form of prion protein in synaptic 102 
structures[24].    103 
In the present study, we quantified CSF neurogranin in CJD and AD cases in order to comparatively 104 
unveil its diagnostic and prognostic potential. We also characterized the presence of neurogranin in 105 
CJD and AD brains to investigate the underlying pathological conditions in the central nervous 106 
system that may lead to the observed disease-specific CSF signatures. 107 
 108 
 109 
 110 
METHODS 111 
Antibodies 112 
The monoclonal neurogranin antibody Ng2 was produced using KLH-conjugated peptide Ng52–75 as 113 
immunogen, as described previously[14] and was used (1:400) for immunohistochemistry (IHC). The 114 
neurogranin antibody Ng36 was generated using the same protocol, but with KLH-conjugated peptide 115 
Ng63-75 as immunogen and was used for western blot (1:6000). Antibodies against sodium-116 
potassium adenosine triphosphatase (ATPaseNa/Kβ, Affinity-MA3-930;1:2000), glyceraldehyde3-117 
phosphate dehydrogenase (GAPDH, Abcam ab9485;1:2500), postsynaptic density protein 95 (PSD-95, 118 
Thermo-Fisher-7E3-1B8;1:1000), synaptophysin (SYNP, Novocastra-NCL-L-SYNAP-299;1:4000), 119 
total-tau (tTau, Sigma-T5530;1:500) and beta-actin (β-actin, Sigma-A5316;1:30000) were used in the 120 
western blot experiments. 121 
Patients and CSF sampling 122 
Neurological controls (NC) were composed of patients diagnosed with a neurological or psychiatric 123 
disease non-associated with a primarily neurodegenerative disease, and were diagnosed according to 124 
acknowledged standard neurological clinical and para-clinical findings based on the 10th revision of 125 
the International Statistical Classification of Diseases definitions. NC include the following diagnoses: 126 
alcohol abuse, astrocytoma, bipolar disorder, cerebral lymphoma, cerebral vasculitis, depression, 127 
epilepsy, Graves’ disease, acute or chronic headache, acute hypoxia, ischemic stroke, meningitis, 128 
multiple infarct, pain syndromes, paraneoplasia, paranoid psychosis, peripheral polyneuropathy, 129 
psychosis, schizophrenia, vascular encephalopathy, vasculitis and vertigo. AD was diagnosed 130 
according to the National Institute on Aging-Alzheimer's Association workgroups(NIA-AA) 131 
criteria[25]. CJD was diagnosed according to consensus criteria[26], 60 definite and 21 probable CJD 132 
cases were included. All CSF samples were collected at the Clinical Dementia Center and the 133 
National Reference Center for CJD Surveillance in the Department of Neurology of the University 134 
Medical Center of Göttingen, Germany. 135 
Lumbar punctures (LPs) were performed for diagnostic purposes at the first evaluation. For disease 136 
stage, samples were stratified in three categories according to whether CSF was collected in the first 137 
(early) (time of LP to disease onset/total duration of the disease < 0.33), second (middle) (0.33–0.66) 138 
or third (last) (> 0.66) stage of the disease. Disease duration was recorded as the time (in months) 139 
from symptom onset to the death of the patient. 140 
Brain samples 141 
Brain tissue was obtained from the Institute of Neuropathology HUB-ICO-IDIBELL-Biobank 142 
following the guidelines of Spanish legislation on this matter (Real Decreto de Biobancos 1716/2011). 143 
Control cases had not suffered from neurologic or psychiatric diseases, infections of the nervous 144 
system, brain neoplasms, or systemic and central immune diseases, and did not have abnormalities in 145 
the neuropathological examination. Neurofibrillary tangles stages were categorized according to 146 
Braak and Braak modified for paraffin sections[27]. CJD cases underwent neuropathological 147 
diagnosis according to established neuropathological criteria[28]. Information about brain cases used 148 
in this study is detailed in Supplementary Table 1. CSF was not available for study in any of the post-149 
mortem brain series. 150 
CSF analyses 151 
Neurogranin and NFL were quantified using two in-house enzyme-linked immunosorbent assay 152 
(ELISA) as described before[13,29]. Total-tau (tau) was quantified using the ELISA kit 153 
INNOTEST®hTAU-Ag (Fujirebio Europe, Ghent, Belgium). CSF was analyzed for the presence of 154 
14-3-3 protein by Western blot according to established CJD diagnostic protocol[30]. The analysts 155 
were blinded to clinical data.  156 
Immunohistochemistry 157 
De-waxed sections, 4 micrometer thick, were processed for immunohistochemistry and incubated at 158 
4ºC overnight with one of the primary antibodies and then incubated with R.T.U. Biotinylated 159 
Universal Antibody (Vector,BP1400) for 30 min at room temperature followed by R.T.U. HRP-160 
Streptavidin (Vector,SA-5704). The peroxidase reaction was visualized with diaminobenzidine and 161 
hydrogen peroxidase. Control of the immunostaining included omission of the primary antibody. 162 
Immunostaining of neurogranin levels were quantified using Image J software, using thresholding tool 163 
settings to subtract background and allow quantification of neuronal neurogranin. 164 
Brain homogenates, subcellular fractionation and western blot. 165 
The purification of PSD fractions from human post-mortem brain tissue was performed as published 166 
before[31]. Brain homogenates and fractions were mixed with SDS-PAGE sample buffer, boiled, and 167 
subjected to 8-15% SDS-PAGE. Gels were transferred onto nitrocellulose membranes and probed for 168 
specific immunodetection by chemiluminescence (ECL-Amersham) using the indicated antibodies. 169 
Densitometries were carried out with the ImageJ software and for brain homogenates values were 170 
normalized using β-actin or GAPDH levels. Since Neurogranin was expressed in all subcellular 171 
fractions, difference among NC, AD and CJD cases was determined in the input. Brain homogenates 172 
were mixed with NuPAGE (Thermo-Fisher) LDS buffer and Reducing Agent, boiled and subjected to 173 
electrophoresis in NuPAGE Bis-Tris 4-12% gels (Thermo-Fisher). Proteins were transferred to 174 
polyvinylidene difluoride (PVDF) membranes and immunodetection was performed as mention above. 175 
Densitometries were determined with the ImageJ software and were normalized using β-actin levels. 176 
Statistical tests 177 
According to distributional features, Mann-Whitney U tests or unpaired t-tests were used to compare 178 
two groups of samples; Kruskal-Wallis test followed by Dunn’s post-hoc tests or ANOVA test 179 
followed by Tukey’s post-hoc tests was applied for multiple comparisons. To assess the diagnostic 180 
accuracy of neurogranin in the discrimination of the diagnostic groups, receiver operating 181 
characteristic (ROC) curve analyses were carried out and areas under the curve (AUC) with 95% 182 
confidence intervals (95%CI) were calculated using GraphPad-Prism6.01. The best cut-off values 183 
were estimated based on the Youden index. Spearman rank and Pearson correlation coefficients were 184 
used to assess associations between continuous biomarker levels. Comparison between AUC was 185 
performed using the DeLong's test[32], available in the R package pROC[33]. To determine the 186 
association between neurogranin, NFL and tau concentrations and total disease duration we used a 187 
fractional polynomial approach based on linear regression methodology as provided in the Stata 188 
package “mfp”. The prognostic capacity of potential biomarkers was assessed using Somers’ D, 189 
Harrells’s C (the higher the better the prognosis) and Brier Scores at 12 months (the lower the score, 190 
the better the prognosis) based on Cox regression models. 191 
 192 
RESULTS 193 
CSF neurogranin in AD and CJD 194 
The study population included NC (n=64), AD (n=46) and CJD (n=81) cases. CSF NFL showed a 195 
mild increase in AD (1.3 times of NC;p<0.05) and a marked increase in CJD (4.3 times of 196 
NC;p<0.001). CSF tau showed a moderate increase in AD (3.1 times of NC; p<0.001) while levels in 197 
CJD were very markedly (41 times) higher than in NC (p<0.001). Additionally, increased tau and 198 
NFL concentrations were detected in CJD compared to AD (p<0.001) (Figure 1A) in agreement with 199 
previous studies [34,35]. 200 
Highest neurogranin concentrations were detected in CJD (571±291 pg/mL), followed by AD 201 
(233±191pg/mL) and NC (120±65pg/mL) (Figure 1A). Neurogranin was significantly different in NC 202 
vs. AD (p<0.01), NC vs. CJD (p<0.001) and AD vs. CJD (p<0.001) (Figure 1B). To determine the 203 
diagnostic accuracy of neurogranin in discriminating the three diagnostic groups, pairwise AUCs were 204 
calculated. Neurogranin poorly discriminated AD from NC (AUC=0.73, 95%CI=0.62-0.82), but 205 
displayed high accuracies distinguishing CJD from NC (AUC=0.96, 95%CI=0.93-0.99) and CJD 206 
from AD (AUC=0.85, 95%CI=0.78-0.92) (Figure 1C). In agreement to this, pROC analysis for the 207 
comparison of AUC values indicate that the AUC for the NC vs CJD comparison was significantly 208 
higher than the AUC for the NC vs AD (p<0.001). A cut-off of 285 pg/mL revealed 89% sensitivity 209 
and 92% specificity for the discrimination of CJD from NC in the study population. In comparison, 210 
diagnostic accuracy of 14-3-3 and tau in the discrimination of CJD from NC was 89% sensitivity/95% 211 
specificity (14-3-3) and 91% sensitivity/98% specificity (tau). 212 
The diagnostic value of neurogranin in the discrimination of CJD from NC (AUC=0.96) was 213 
statistically lower than the one for tau (AUC=0.99, 95%CI=0.97-1, pROC neurogranin vs tau, 214 
p=0.012), but higher than the one for NFL (AUC=0.89, 95%CI=0.83-0.95, pROC neurogranin vs 215 
NFL p=0.041).  216 
The diagnostic value of neurogranin in the discrimination of CJD from AD (AUC=0.85) was lower 217 
than the one for tau (AUC=0.94, 95% CI=0.91-0.99, pROC neurogranin vs tau, p=0.001) and not 218 
significantly different than the one for NFL (AUC=0.84, 95%CI=0.76-0.91, pROC neurogranin vs 219 
NFL, p=0.84). 220 
Next, we compared the accuracy of neurogranin in the discrimination of CJD from rapidly progressive 221 
AD(rpAD), which turns to be challenging in clinical scenario. AD cases with available data on disease 222 
duration (n=32) were stratified in those with disease survival shorter (rpAD, n=11) and longer  (AD, 223 
n=21) than 2 years following the definition of Grau-Rivera et al. for rapidly progressive dementia [36]. 224 
Neurogranin concentrations were higher in rpAD (256pg/mL) than in AD (214pg/mL), but those were 225 
not significantly different (p=0.47). Similarly, neurogranin was not significantly different for the CJD 226 
vs. AD (p<0.001) and CJD vs. rpAD (p<0.001) comparisons. 227 
Influence of demographic and genetic parameters on neurogranin concentrations 228 
Neurogranin concentrations in CJD were neither affected by age at LP (ranging from 43 to 90 years 229 
old, rho=0.05, p=0.64) (Figure 2A) nor by the sex of the patients (p=0.80) (Figure 2B). Similarly, no 230 
strong associations between neurogranin and age at LP and sex were detected in NC (age at 231 
LP:p=0.27, sex:p=0.16), and AD (age at LP:p=0.18, sex:p=0.77) (Figure 2A and Figure 2B). To test 232 
whether genetic characteristics of the patients were associated with differential neurogranin 233 
concentrations, we stratified CJD samples by prion protein gene (PRNP) codon 129 genotype (data 234 
available for 65 cases), a well-known CJD risk factor and disease modifier[37]. Mean neurogranin 235 
concentrations were significantly lower in valine/valine [VV] (n=14, 384±172pg/mL) compared to 236 
methionine/methionine [MM] (n=38, 630±318pg/mL) and methionine/valine [MV] (n=13, 237 
640±249pg/mL) cases (p<0.05) (Figure 2C). To explore whether neurogranin was associated with 238 
prion disease subtype, we further stratified CJD cases with known prion subtype achieved through 239 
post-mortem brain tissue analysis (n=28). CJD MM1/MV1 (n=15) and VV2 (n=8) cases, representing 240 
the two most prevalent CJD subtypes were studied. Due to their low number, other subtypes were not 241 
included in the analysis. Neurogranin concentrations were significantly higher in CJD MM1/MV1 242 
(718±306 pg/mL) compared to CJD VV2 (373±160 pg/mL) (p<0.01) (Figure 2D). 243 
Correlations between neurogranin, surrogate prion biomarkers and clinical data 244 
In CJD, CSF neurogranin showed a good correlation with tau (rho=0.55, p<0.001), but did not 245 
correlate with NFL (rho=0.08, p=0.46) (Figure 3A). Additionally, tau and NFL displayed a positive 246 
but weak correlation (rho=0.26, p=0.01), in agreement with previous reports[34]. CJD cases 247 
displaying positive 14-3-3 test presented higher neurogranin levels than those showing no 14-3-3 (or 248 
traces) signal in the western blot test (p<0.05) (Figure 3B).  249 
To study a potential association between neurogranin levels at the time of lumbar puncture and the 250 
timeliness of the disease in CJD patients, samples were stratified in early, middle and late stages. 251 
Neurogranin concentrations were not significantly different between early (n=9, 510±292 pg/mL), 252 
middle (n=26, 576±294 pg/mL) or late (n=28, 635±319 pg/mL) disease stages (Figure 3C). 253 
Next we assessed the potential role of neurogranin as a biochemical marker of disease survival in 63 254 
CJD cases where disease duration was available, and compared it with the performance of tau and 255 
NFL. When allowing for non-linear associations between biomarker levels and disease duration, 256 
neurogranin was able to explain more of the variability in disease duration (R2=0.19) than tau 257 
(R2=0.10) and NFL (R2=0.07). All three biomarkers showed a log-linear decrease with increasing 258 
disease duration (Figure 3E for neurogranin). For neurogranin, the association with survival time can 259 
be modelled using a linear combination of the terms: neurogranin (in g/ml) =533+1/(47*[survival 260 
time in months-1.6])-28*[survival time in months-0.6]; it showed a good ability as a prognostic 261 
marker, represented by  Somers' D value of 0.32; Harrell's C value of 0.66 and a Brier score at 12 262 
months of 0.09. For tau and NFL, similar values were achieved (tau: Somers’ D=0.27, Brier 263 
score=0.11; NFL: Somers’ D=0.16, Brier score=0.09). In AD, total disease duration was available in 264 
32 cases, in which neurogranin values were also associated with disease (as well via a log-linear 265 
decline, R2=0.32).  266 
Neurogranin expression in brain tissue  267 
In human brain tissue of control cases, neurogranin was highly expressed in the neuronal soma of the 268 
cerebral cortex (n=13) and hippocampus (n=6), but absent in the white matter (n=13) and cerebellum 269 
(n=8) (Figure 4A). To further study neurogranin subcellular levels, different brain fractions from 270 
control cases (n=4) were purified. Neurogranin was detected in the cytoplasmic (41 ± 5%), membrane 271 
(32 ± 4%) and post-synaptic density (PSD) (27 ± 2%) fractions. As control proteins for each fraction 272 
we used PSD-95 (post-synaptic), ATPase Na/K (plasma membrane) and synaptophysin (pre-synaptic) 273 
for membrane fraction and GAPDH (cytoplasm) (Figure 4B). 274 
Neuronal neurogranin levels were analyzed in the cerebral cortex (control,n=10, AD,n=10, CJD,n=9) 275 
and hippocampus (control,n=6, AD,n=7, CJD,n=5) (Figure 5A). A multiple-comparative tests analysis 276 
of neurogranin expression from immunohistochemical analysis revealed a significant decrease in CJD 277 
(p<0.001) and AD (p<0.001) compared to controls in both brain regions (Figure 5B). Additionally, 278 
neurogranin immunostaining in CJD was significantly lower than in AD in both brain regions (p<0.01 279 
in cerebral cortex and p<0.05 in hippocampus). No statistical differences were detected in neurogranin 280 
levels between Braak stages IV (n=3), V (n=4) and VI (n=3), indicating that alterations in neurogranin 281 
expression were not an end-stage feature on AD pathology (Figure 5A). 282 
Reduction of neurogranin levels in the frontal cortex of CJD MM1 (n=10) and VV2 (n=10) cases 283 
compared to controls (n=8) was validated by western blot analysis and accompanied by decreased 284 
levels of post-synaptic (PSD-95), pre-synaptic (synaptophysin) and axonal (tau) markers (Figure 6A 285 
and 6B). Compared to controls, and similar to PSD-95, synaptophysin and tau, decreased neurogranin 286 
levels were more severe in CJD MM1 (p<0.001) than VV2 cases (p<0.05) (Figure 6B). Neurogranin 287 
in CJD (n=20) correlated significantly with tau and PSD-95 (p<0.001) and with synaptophysin 288 
(p=0.01). All four proteins presented close correlations with each other (Figure 6C). 289 
Neurogranin levels by means of western blot analysis in the frontal cortex region of AD cases (n=18) 290 
were also reduced significantly compared to controls (n=23, p<0.01). Moderate decreases in synaptic 291 
proteins PSD-95 (p<0.01) and synaptophysin (p<0.01) were detected, while tau levels were not 292 
altered (Figure 7A and 7B). Neurogranin in AD (n=18) significantly correlated with synaptophysin 293 
(p<0.001) and PSD-95 (p<0.05) but not with tau (p>0.05). An additional correlation was detected 294 
between PSD-95 and synaptophysin (p=0.01) (Figure 7C). No significant associations between age, 295 
sex, post-mortem time delay and neurogranin levels measured by western-blot were found in controls, 296 
CJD and AD cases. 297 
 298 
DISCUSSION 299 
In this study, we demonstrate that CSF neurogranin is increased in CJD compared to NC (4.75 fold 300 
change) and AD (2.5 fold change), reaching good diagnostic accuracies in the discrimination of CJD 301 
from AD (AUC=0.85, 95% CI=0.78-0.92). The increased CSF neurogranin concentrations detected in 302 
CJD compared to AD is in line with the lower neurogranin levels detected in the cerebral cortex and 303 
hippocampus of CJD cases, and with the well-known higher neuronal damage present in CJD 304 
compared to AD. 305 
In CJD, CSF neurogranin concentrations at early disease stages were not different from those detected 306 
at middle and late stages, indicating that synaptic damage is an early event in CJD, similar to what 307 
previously has been found for AD[8]. Indeed, the observation that neurogranin levels in AD brain 308 
tissue were not different between early and late Braak stages further supporting that synaptic loss, as 309 
measured by neurogranin, is not a late stage pathological event. In this regard, it is well known that 310 
synaptic damage is an early event in AD [38]. 311 
In our study population, CSF neurogranin correlated neither with age nor with sex in any of the 312 
diagnostic groups but we detected differences in CJD cases regarding codon 129PRNP polymorphism 313 
and subtype with potential clinical implications. First, neurogranin concentrations were significantly 314 
higher in CJD MM and MV compared to VV cases, in contrast to tau, which shows higher 315 
concentrations in MM and VV, compared to MV cases [39]. Since codon 129PRNP data are pre-316 
mortem available, the combined analysis of tau and neurogranin could led to specific codon 129PRNP 317 
polymorphism-dependent cut-offs enhancing the discriminatory value of single biomarker 318 
measurements. Second, CJD MM1/MV1 cases, two subtypes with similar clinco-pathological 319 
phenotype, displayed higher CSF neurogranin concentrations than VV2. As described before[21] and 320 
in the present study, synaptic and neuroaxonal damage is higher in CJD MM1/MV1 than in VV2 in 321 
cortical regions, where neurogranin is highly expressed. Thus, it is tempting to speculate that CSF 322 
neurogranin levels reflect the neuropathological heterogeneity of CJD prion subtypes regarding 323 
synaptic and neuronal loss. In this regard, biomarkers such as neurogranin, able to recapitulate the 324 
heterogeneity of CJD pathology, may turn into valuable markers for disease diagnosis, prognosis and 325 
for, monitoring potential therapeutic approaches and inclusion of patient populations in clinical trials. 326 
Limitations of this study were the low number of CJD cases with subtype available and the absence of 327 
CSF-brain paired cases. Thus, further analysis including less prevalent subtypes and paired cases 328 
should be carried out to determine the complete neurogranin profile in the spectrum of CJD cases and 329 
its association with neuropathological correlates.  330 
Compared to 14-3-3, one of the gold standards CSF biomarkers for CJD, neurogranin presented 331 
similar diagnostic accuracies in the discrimination of CJD from controls. In contrast, tau showed a 332 
much more fold change (41 times as compared with 4.75 times for neurogranin) and higher diagnostic 333 
accuracy than neurogranin in the discrimination of CJD cases from NC and AD. However, 334 
neurogranin explained more of the variance in disease duration than tau and NFL. Further studies 335 
should clarify the precise value of neurogranin over tau and other described prognostic markers for 336 
CJD[34,40] and its precise context of use in disease monitoring and evaluation of eventual therapeutic 337 
therapies. Similarly, in the AD cases, neurogranin was also associated with disease survival, 338 
validating previous reports in which neurogranin was proposed as a marker of AD outcome[8,41].  339 
An interesting finding from our study is the observation that neurogranin is broadly present in 340 
different neuronal fractions/compartments. Immunohistochemical analysis was supported by 341 
biochemical studies where we detected similar neurogranin levels in the cytoplasmic, membrane and 342 
post-synaptic fractions. The fact that only a percentage (27%) of total neurogranin is expressed in the 343 
post-synaptic fraction calls attention to its proposed use as post-synaptic damage marker, and suggests 344 
a dual role as a synaptic and neuroaxonal damage marker. 345 
Our studies in brain tissue also indicated a major overlap between neurogranin and tau expressing 346 
neurons in the cerebral cortex (data not shown), which explains the high degree of association 347 
between both proteins in the CSF of CJD cases, where major neuronal damage occurs. Likewise, the 348 
absence of a clear correlation between CSF neurogranin and NFL in CJD can be explained by the lack 349 
of overlap between the levels of both proteins in the brain tissue. In this regard, NFL expression is 350 
mainly reported in the axons of the white mater region[42] where neurogranin staining was 351 
undetectable in our cases. Additionally, these results are in agreement with the recent observation that 352 
NFL in the CSF, in contrast to neurogranin, is more increased in CJD VV2 cases than in MM1[34], 353 
with VV2 cases showing higher subcortical pathology compared with other CJD subtypes[43]. Indeed, 354 
neurogranin paralleled the CJD subtype-dependent reduced expression levels of PSD-95, 355 
synaptophysin and tau, showing a significant correlation with all the studied proteins, especially with 356 
tau and PSD-95. Whether these associations are relevant for the neurodegenerative process in CJD 357 
remains unknown due to the rapid and massive synaptic and neuronal damage occurring in this 358 
pathology. In contrast, reduction of synaptic markers was only moderate in AD brain, while tau levels 359 
were unchanged, most likely due to its aggregation in the brain tissue. Moderate decline on synaptic 360 
markers in AD tissue observed in our study was not surprising. While synaptophysin was reported to 361 
be decreased (≈25%) in the cortex of mild AD patients[44], recent studies revealed only a moderate 362 
decline in synaptic markers, including PSD-95 and synaptophysin in the prefrontal cortex (BA9) of 363 
patients with AD at advanced cognitive deterioration[45].  364 
Similar to CJD, neurogranin levels in AD correlated with both synaptic markers. On the one hand, this 365 
indicates that neurogranin, while not specifically expressed in synapsis, but rather in several neuronal 366 
compartments, could be a synaptic dysfunction marker in AD and CJD. On the other hand, our data 367 
also suggest that both pre and post-synaptic dysfunction can be surveyed through the evaluation of 368 
biological fluids. In this regard, it would be interesting to determine whether novel biomarkers that 369 
may be more specific to the synapse[46–48] are differentially altered in AD and CJD and better 370 
reflect synaptic damage than neurogranin. 371 
Recently, the presence of increased neurogranin processing peptides and decreased full-length protein 372 
has been reported in AD brain tissue[49]. These observations suggest that neurogranin processing in 373 
AD may reflect both synaptic and axonal damage. Since neurogranin was associated with tau and 374 
amyloid pathology, it would be interesting to study whether a similar proteolytic pattern is observed 375 
in CJD, where neurogranin levels are altered in brain and CSF tissue without the presence of AD 376 
pathological hallmarks.  377 
In total, this study evaluates for the first time the diagnostic and prognostic value of CSF neurogranin 378 
in CJD in comparison to AD. Additionally, we show a striking correlation between brain and CSF 379 
findings regarding different diseases (CJD vs AD) and CJD subtypes (MM1/MV1 vs VV2). This 380 
strongly supports the usefulness of comparative analysis between brain and biological fluids to 381 
comprehensively understand the molecular mechanisms underlying neurodegenerative dementias and 382 
the associate value of their study as diagnostic and prognostic markers for these conditions. 383 
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FIGURE LEGENDS 556 
Figure 1. Analysis of CSF neurogranin levels in the differential diagnosis of AD and CJD. 557 
(A) Demographic and biomarker characteristics of the CSF cases used in the present study. Number 558 
of cases, sex (f: female, m: male), age, semi-quantitative analysis of 14-3-3 protein (pos: positive, neg: 559 
negative) and quantitative analysis of neurogranin, total tau (tau) and neurofilament light (NFL) 560 
(mean ± standard deviation (SD)) are indicated. NC: Neurological controls, AD: Alzheimer’s disease 561 
and CJD: sporadic Creutzfeldt-Jakob disease. (B) Neurogranin concentrations in NC, AD, and CJD. 562 
Neurogranin was significantly different in ND vs AD (p<0.01), NC vs CJD (p<0.001) and AD vs CJD 563 
(p<0.001) comparisons. Statistical significance derived from a multi-comparison analysis for tau, 564 
NFL and neurogranin among the diagnostic groups is indicated. Kruskal-Wallis test followed by 565 
Dunn’s post-test (correction for multiple testing) was applied. (C) Diagnostic accuracy of CSF 566 
neurogranin in the discrimination of NC, AD and CJD groups. Area Under the Curve (AUC) with 567 
Standard Error (Srtd. Error) and 95% Coefficient of Interval (CI) derived from Receiver Operating 568 
Characteristic curves for the comparisons between pairs of diagnostic groups is shown. *p<0.05, 569 
**p<0.01 and ***p<0.001. 570 
Figure 2. Association between neurogranin, demographic and genetic factors in the study 571 
population in CJD. 572 
(A) No correlation was found between neurogranin levels and age at disease onset in CJD cases. (B) 573 
Neurogranin concentrations did not correlate with sex distribution in CJD cases. Spearman rank 574 
correlation and unpaired t-test analysis were used respectively. (C) Neurogranin concentrations in 575 
CJD stratified by prion protein gene (PRNP) codon 129 polymorphism (M = Methionine, V = Valine, 576 
MM, n=38, MV: n=13, VV: n=14). Kruskal-Wallis test followed by Dunn’s post-test (correction for 577 
multiple testing) was applied (*p<0.05 for MM vs VV and MV vs VV comparisons). (D) Neurogranin 578 
concentrations in sCJD MM1/MV1 (n=15) and VV2 (n=9) subtypes. Unpaired t-test analysis was 579 
applied (**p<0.01 for MM1/VV1 vs VV2 comparison).  580 
Figure 3. Association between neurogranin, prion biomarkers and clinical data in CJD. 581 
(A) Correlation analysis between neurogranin, tau and NFL concentrations in CJD cases. Spearman’s 582 
rho and p values are indicated for each comparison. Positive significant associations were detected 583 
between neurogranin and tau (p<0.001) and between tau and NFL (p<0.01). (B) Neurogranin 584 
concentrations in CJD stratified by 14-3-3 protein testing outcomes. Negative test was considered 585 
when absence or trace of 14-3-3 protein was detected in the western blot analysis. Mann-Whitney U 586 
test was used. CJD cases with positive 14-3-3 test displayed higher neurogranin concentrations than 587 
CJD cases with negative 14-.3-3 test (*p<0.05). (C) Neurogranin concentrations stratified by disease 588 
stage (early, middle and late) in CJD cases. No statistical differences between disease stages were 589 
detected. Kruskal-Wallis test followed by Dunn’s post-test (correction for multiple testing) was 590 
applied. (E) Association between neurogranin concentrations and disease duration (months) in CJD 591 
patients using a fractional polynomial approach based on a linear regression model. Disease duration 592 
can be modelled as a function of neurogranin values based on the formula: neurogranin (in g/ml) = 593 
533 + 1/(47*[survival time in months-1.6]) -28*[survival time in months-0.6]. 594 
Figure 4. Neurogranin expression in control brain tissue. 595 
(A) Immunohistochemical analysis of neurogranin expression in the cerebral cortex (n=13), white 596 
matter (n=13), cerebellum (n=8) and hippocampus (n=6) of control brain tissue. Neurogranin 597 
immunoreactivity was present in the cerebral cortex and hippocampus and absent in white matter and 598 
cerebellum regions. Bar: 50 m. (B) Cell fractionation analysis of human frontal cortex cases (n=4) 599 
by differential centrifugation. Input and cell fractions (Cyt: cytoplasm, Memb: membrane, PSD: post-600 
synaptic-density) were separated by SDS–PAGE, followed by immunoblotting with neurogranin, 601 
PSD-95, ATPase Na/KGAPDH and synaptophysin antibodies as specific markers of each cellular 602 
fraction (left panel). Quantification analysis relative to the % of protein detected in each cell fraction 603 
is indicated (right panel). 604 
Figure 5. Neurogranin expression in AD and CJD brain tissue. 605 
(A) Immunohistochemical analysis of neurogranin expression in the cerebral cortex and hippocampus 606 
of control, CJD and AD brain tissue. Bar: 50 m. (B) Quantification of immunohistochemical staining 607 
of neuronal neurogranin from figure 5A. Cerebral cortex: control; n=10, AD; n=10, CJD; n=9. 608 
Hippocampus: control; n=6, AD; n=7, CJD; n=5. Neurogranin expression in both regions was 609 
decreased in controls compared to AD and CJD (p<0.001 for all the comparisons) and in AD 610 
compared to CJD (p<0.01 in cerebral cortex and p<0.05 in hippocampus). ANOVA test followed by 611 
Tukey’s post-hoc was applied. *p<0.05, **p<0.01 and ***p<0.001. (C) Quantification of 612 
immunohistochemical analysis from AD cases according to Braak stage. AD IV; n=3, AD V; n=4; 613 
AD VI; n=3. ANOVA test followed by Tukey’s post-hoc was applied. 614 
Figure 6. Neurogranin expression in CJD and association with synaptic and axonal markers. (A) 615 
Western blot analysis of PSD-95, tau, synaptophysin, neurogranin and -actin in the frontal cortex of 616 
control, sCJD MM1 and sCJD VV2 cases. A representative image (4 controls, 5 CJD MM1 and 5 617 
CJD VV2) is shown. (B) Quantification of the western blot analysis from the complete cohort of cases 618 
analyzed, which included: controls; n=8, CJD MM1; n=10 and CJD VV2; n=10. ANOVA test 619 
followed by Tukey’s post-hoc was applied. PSD-95, tau, synaptophysin and neurogranin levels was 620 
reduced in CJD cases compared to controls (*p<0.05, **p<0.01 and ***p<0.001). (C) Correlation 621 
analysis of Neurogranin with tau, synaptophysin and PSD-95 in CJD cases (n=20) (left panel) and 622 
correlation values (rho, 95% CI and p value) for each comparison between pair of proteins (right 623 
panel). 624 
Figure 7. Neurogranin levels in AD and association with synaptic and axonal markers. 625 
Western blot analysis of PSD-95, tau, synaptophysin, neurogranin and -actin in the frontal cortex of 626 
control, and AD cases. A representative image (4 controls and 4 AD) is shown. (B) Quantification of 627 
the western blot analysis from the complete cohort of cases analyzed (controls; n=23, AD; n=18). 628 
ANOVA test followed by Tukey’s post-hoc was applied. PSD-95synaptophysin and neurogranin 629 
expression was reduced in AD cases compared to controls (*p<0.05, **p<0.01 and ***p<0.001). (C) 630 
Correlation analysis of Neurogranin with tau, synaptophysin and PSD-95 in AD cases (n=18) (left 631 
panel) and correlation values (rho, 95% CI and p value) for each comparison between pair of proteins 632 
(right panel). 633 
 634 
Supplementary Table 1. Demographic, neuropathological genetic characteristics of the brain 635 
cases used in the present study. (A) Controls, (B) AD and (C) CJD. Number of cases, age at onset, 636 
sex (f: female, m: male), and post-mortem time delay (PMT) is indicated. Braak neurofibrillary tangle 637 
(NFT) stage in AD cases and CJD subtype in CJD cases is indicated. FC(R8): frontal cortex 638 
Brodmann region 8, HPC: hippocampus, CB: cerebellum. IHC: Immunohistochemistry, WB: Western 639 
blot, PSD: Post-synaptic density. 0 and B refers to amyloid stage.     640 
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Std. Error 0.05 0.01 0.03
95% CI 0.62-0.82 0.93-0.99 0.78-0.92
NC AD CJD
10
100
1000
10000
N
e
u
ro
g
ra
n
in
 (
p
g
/m
L
)
*** 
** ** 
NC AD CJD
Number of cases 64 46 81
Sex (number, f/m) 33/31 27/19 47/34
Age (mean ± SD, years) 65 ± 11 66 ± 9 67 ± 10
14-3-3 (number, pos/trace/neg) 3/4/57 9/3/34 72/4/5
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Supplementary Table 1
Frontal Cortex ID Age (years) Sex PMT (hours) Neuropathological findings IHC WB PSD
1 41 F 12h Not available X
2 53 M 3h No neuropathological lesions X X
3 70 M 12h No neuropathological lesions X X
4 55 M 5h 40m Not available X
5 59 M 7h 5m No neuropathological lesions X
6 39 M 9h 15m Infarction, lacunar X X
7 46 F 14h 5m Not available X
8 59 M 6h 25m No neuropathological lesions X
9 71 F 8h 30m Neurofibrillary tangle pathology I, 0 X
10 43 M 5h 55m No neuropathological lesions X
11 39 M 3h 30m Argyrophilic grain disease III X X X
12 56 M 3h 50m Multi-infarct X
13 71 M 15h Neurofibrillary tangle pathology I, 0 X
14 79 F 3h 35m Neurofibrillary tangle pathology I, 0 X
15 55 M 2h 45 m Infarction, lacunar X
16 49 M 09h 25 m Neurofibrillary tangle pathology, scant X
17 62 M 19h 55 m No neuropathological lesions X
18 50 F 14h 30 m Hyphoxia, hippocampus X
19 72 F 8h 30m Neurofibrillary tangle pathology II, 0 X
20 50 M 17h 15m No neuropathological lesions X
21 54 F 6h 45m Ischaemic changes hippocampus
22 52 M 4h 40m No neuropathological lesions X X
23 52 F 5h 45m No neuropathological lesions X
24 61 M 4h 30m Neurofibrillary tangle pathology I, 0 X
25 45 M 4h 5m Cerebral infarction X
26 77 M 6h 55m No neuropathological lesions X
27 73 M 9h 35m Neurofibrillary tangle pathology II, 0 X
28 65 F 15h Neurofibrillary tangle pathology II, B X
29 60 F 11h 30m No neuropathological lesions X
30 72 M 15h 55m Argyrophilic grain disease III X
31 63 M 4 h 5 min Hypoxia X
32 41 M 11h 35m Small vessel disease X X
33 78 M 12h Small vessel disease X
34 72 F 4h Status cribosus X
35 59 M 21h 35m No neuropathological lesions X X
36 59 M 8h 30m Status cribosus X X
37 54 M 8h 45m No neuropathological lesions X
38 72 M 4h 20m No neuropathological lesions X
39 70 M 13h No neuropathological lesions X
40 63 M 17h No neuropathological lesions X
41 59 M 7h No neuropathological lesions X
Hippocampus ID Age (years) Sex PMT (hours) Neuropathological findings IHC WB PSD
1 53 M 15h 20m Neurofibrillary tangle pathology, scant X
2 63 M 17h No neuropathological lesions X
3 53 M 3h No neuropathological lesions X
4 55 M 2h 45m Infarction, lacunar X
5 40 M 5h 10m Neurofibrillary tangle pathology, scant X
6 54 M 8h 45m Calcifications X
Cerebellum ID Age (years) Sex PMT (hours) Neuropathological findings IHC WB PSD
1 39 M 9h 15m No neuropathological lesions X
2 23 M 12h 55m No neuropathological lesions X
3 52 M 04h 40 m No neuropathological lesions X
4 52 F 05h 45 m No neuropathological lesions X
5 62 M 3h 30m Hematoma X
6 42 M 4h 20m No neuropathological lesions X
7 54 M 8h 45m Calcifications X
8 40 M 18h 30m No neuropathological lesions X
M: male, F: female
PMT: Post-mortem time
IHC: Immunhistochemistry, WB: Western blot, PSD: Post-synaptic density
0 and B refers to amyloid stage
A
Supplementary Table 1
Frontal Cortex ID Age (years) Sex PMT (hours) NFT (Braak Stage) IHC WB
1 75 M 6h 10m IV X
2 79 M 5h IV X
3 79 M 4h 15m IV X
4 89 M 3h 20m IV X X
5 84 M 26h IV X
6 72 F 9h 30m V X
7 86 M 4h 15m V X
8 82 F 1h 45m V X
9 73 M 4h 30m V X
10 85 F 16h 15m V X
11 93 M 3h V X
12 75 M 11h 30m V X
13 81 F 5h 15m V X
14 77 M NA V X
15 74 F 9h  V X
16 50 M 9h 15m V X
17 69 M 13h 10m V-VI X
18 64 M 6h 10m V-VI X
19 67 F 6h 10m V-VI X
20 82 M 5h  V-VI X
21 86 F 20 h 35 m VI X X
22 67 F 8h VI X
23 56 F 7 h VI X X
24 88 M 4h 45m VI X X
Hippocampus ID Age (years) Sex PMT (hours) NFT (Braak Stage) IHC WB
1 72 F 16h 10m IV X
2 84 M 26h IV X
3 75 M 11h 30m V X
4 88 M 4h 45m V X
5 50 M 9h 15m V X
6 84 F 21h V X
7 56 F 7h VI X
M: male, F: female
PMT: Post-mortem time
IHC: Immunhistochemistry, WB: Western blot, PSD: Post-synaptic density
B
Supplementary Table 1C
Frontal Cortex ID Age (years) Sex PMT (hours) CJD Subtype IHC WB
1 44 M 6h 30 m MM1 X
2 46 M 4h 45m MM1 X X
3 59 M 21 h MM1 X X
4 57 M 4h 15 m Not available X
5 56 F 13h 30m MV2 X
6 61 M 30h 30m MM1 X
7 64 M 40h Not available X
8 66 M NA VV2 X
9 59 M 10h MV2 X
10 72 F 8h MM1 X
11 85 F NA MM1 X
12 59 F 15h MM1 X
13 60 F 5h 30m MM1 X
14 65 F 5h 30m MM1 X
15 76 M 18h 30m MM1 X
16 78 M 23h MM1 X
17 25 M 4h MM1 X
18 66 M 5h VV2 X
19 71 M 9h VV2 X
20 76 F 5h VV2 X
21 76 F 5h 30m VV2 X
22 51 F 6h VV2 X
23 65 M VV2 X
24 73 F 24h VV2 X
25 47 F 5h 30m VV2 X
26 54 M 9h VV2 X
27 65 F 7h VV2 X
Hippocampus ID Age (years) Sex PMT (hours) CJD Subtype IHC WB
1 57 M 4 h 15 m MM1 X
2 56 F 13h 30m MM2 X
3 72 F 17h MM1 X
4 74 M 2h MM1 X
5 61 M 30h 30m Not available X
M: male, F: female
PMT: Post-mortem time
IHC: Immunhistochemistry, WB: Western blot, PSD: Post-synaptic density
